飯嶋寿江　IIJIMA TOSHIE　イイジマ トシエ

研究者情報

研究者情報

• 氏名

  飯嶋寿江, イイジマ トシエ

所属

• 内科学(内分泌代謝)(壬生), 学内講師

研究業績

論文

原著論文
• Circulating CD4+PD-1+ and CD8+PD-1+ T cells are profoundly decreased at the onset of fulminant type 1 diabetes and are restored by treatment, contrasting with CD4+CD25+FoxP3+ regulatory T cells., Iijima T, Kato K, Jojima T, Tomotsune T, Fukushima M, Suzuki K, Aso Y, Diabetes Res Clin Pract, 133, 10-12, 2017年11月

  DOI
• Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice., Jojima T, Uchida K, Akimoto K, Tomotsune T, Yanagi K, Iijima T, Suzuki K, Kasai K, Aso Y, Atherosclerosis , 261, 44-51, 2017年06月

  DOI
• Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes., Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y, Diabetol Metab Syndr, 8, 45, 2016年07月

  DOI
• Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34?CXCR4? cells in patients with type 2 diabetes., Aso Y, Jojima T, Iijima T, Suzuki K, Terasawa T, Fukushima M, Momobayashi A, Hara K, Takebayashi K, Kasai K, Inukai T, Endocrine., 50（3）, 659-664, 2015年12月

  DOI
• The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes, Aso Y, Terasawa T, Kato K, Jojima T, Suzuki K, Iijima T, Kawagoe Y, Mikami S, Kubota Y, Inukai T, Kasai K, Transl Res, 162（5）, 309-316, 2013年11月

  DOI
• 当院における高カルシウム血症の病因・病態の解析と治療 高カルシウム血症クリーゼも含めて, 作田亜有子, 飯嶋寿江, 百目木希実, 鈴木國弘, 加瀬浩之, 川越宣明, 笠井貴久男, Dokkyo J Med Sci, 39（1）, 45-55, 2012年03月
• Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis., Sakurai Shintaro;Jojima Teruo;Iijima Toshie;Tomaru Takuya;Usui Isao;Aso Yoshimasa, Journal of diabetes and its complications, 34（11）, 107703, 2020年

  DOIPermalink
• Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes., Aso Yoshimasa;Kase Masato;Sagara Masaaki;Sakurai Shintaro;Iijima Toshie;Tomaru Takuya;Jojima Teruo;Usui Isao, The American journal of the medical sciences, 360（3）, 261-267, 2020年

  DOIPermalink
• Acute effect of add-on therapy with tofogliflozin, a sodium glucose co-transporter 2 inhibitor, on 24-hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase-4 inhibitors., Iijima Toshie;Hosonuma Soichiro;Kurai Hidetaka;Kajitani Hayato;Sakurai Shintaro;Tomaru Takuya;Jojima Teruo;Usui Isao;Aso Yoshimasa, International journal of clinical practice, 75（11）, e14732, 2021年08月19日

  DOIPermalink
• Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease., Aso Yoshimasa;Sagara Masaaki;Niitani Takafumi;Kato Kanako;Iijima Toshie;Tomaru Takuya;Jojima Teruo;Usui Isao, Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 69（7）, 1324-1329, 2021年05月20日

  DOIPermalink
• Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis., Sagara Masaaki;Iijima Toshie;Kase Masato;Kato Kanako;Sakurai Shintaro;Tomaru Takuya;Jojima Teruo;Usui Isao;Aso Yoshimasa, Journal of diabetes and its complications, 35（5）, 107885, 2021年02月06日

  DOIPermalink
• No Negative Impact of a National State of Emergency by COVID-19 Outbreak on Hemoglobin A1c Levels in Patients With Type 2 Diabetes Living in Semi-Rural Japan., Aso Yoshimasa;Iijima Toshie;Tomaru Takuya;Jojima Teruo;Usui Isao, The American journal of the medical sciences, 362（1）, 104-105, 2021年03月30日

  DOIPermalink
• Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol., Jojima Teruo;Sakurai Shintaro;Wakamatsu Sho;Iijima Toshie;Saito Masahiro;Tomaru Takuya;Kogai Takahiko;Usui Isao;Aso Yoshimasa, International journal of cardiology, 331, 243-248, 2021年02月05日

  DOIPermalink
• Acute Exacerbation of Anemia with Parvovirus B19 Infection One Year after Sleeve Gastrectomy for Severe Obesity., Shinzawa Toshimitsu;Usui Isao;Hanawa Kanako;Kajitani Hayato;Sakurai Shintaro;Tomaru Takuya;Iijima Toshie;Jojima Teruo;Kojima Kazuyuki;Aso Yoshimasa, Internal medicine (Tokyo, Japan), 61（17）, 2631-2635, 2022年02月08日

  DOI
• Switching from the tablet to the powder formulation of levothyroxine corrects severe hypothyroidism in a patient with lactose intolerance., Jojima Teruo;Shinzawa Toshimitsu;Ohira Eriko;Sakurai Shintaro;Tomaru Takuya;Iijima Toshie;Kogai Takahiko;Usui Isao;Aso Yoshimasa, Endocrine journal, 69（8）, 941-945, 2022年03月04日

  DOI
• Effects of treatment with methimazole on circulating CD4+ and CD8+ T cells positive for programed cell death protein-1 and on subsets of CD4+ T cells in untreated hyperthyroid patients with Graves' disease., Hirao Nanako;Iijima Toshie;Tanuma Dai;Ohira Eriko;Kurai Hidetaka;Shinzawa Toshimitsu;Kase Masato;Sakurai Shintaro;Tomaru Takuya;Jojima Teruo;Usui Isao;Aso Yoshimasa, Clinical endocrinology, 97（6）, 841-848, 2022年06月17日

  DOI
• Synergistic effects of liver fibrosis and sarcopenia on endothelial dysfunction and arterial stiffness in patients with type 2 diabetes., Jojima Teruo;Kurai Hidetaka;Tanuma Dai;Kajitani Hayato;Kase Masato;Inoue Yuiko;Sakurai Shintaro;Iijima Toshie;Tomaru Takuya;Usui Isao;Aso Yoshimasa, International journal of cardiology. Heart & vasculature, 41, 101071, 2022年06月16日

  DOI
• Increased Number of Mucosal-Associated Invariant T Cells Is Associated with the Inhibition of Nonalcoholic Fatty Liver Disease in High Fat Diet-Fed Mice., Kishi Haruka;Usui Isao;Jojima Teruo;Fujisaka Shiho;Wakamatsu Sho;Mizunuma-Inoue Yuiko;Niitani Takafumi;Sakurai Shintaro;Iijima Toshie;Tomaru Takuya;Tobe Kazuyuki;Aso Yoshimasa, International journal of molecular sciences, 23（23）, 2022年12月04日

  DOI
• Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor., Wakamatsu Sho;Jojima Teruo;Hashiguchi Masaaki;Kishi Haruka;Niitani Takafumi;Sakurai Shintaro;Iijima Toshie;Kogai Takahiko;Tomaru Takuya;Usui Isao;Aso Yoshimasa, Journal of diabetes and its complications, 38（1）, 108650, 2023年11月23日

  DOI
• Acute Effect of Imeglimin Add-on Therapy on 24-h Glucose Profile and Glycemic Variability in Patients with Type 2 Diabetes Receiving Metformin., Shinohara Yasutake;Jojima Teruo;Kamiga Yusuke;Sakurai Shintaro;Iijima Toshie;Tomaru Takuya;Akutsu Ikuo;Inoue Teruo;Usui Isao;Aso Yoshimasa, Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 33（6）, 569-577, 2024年08月12日

  DOI
• Empagliflozin increases plasma levels of citrulline, histidine, and α-aminobutyric acid in patients with type 2 diabetes: effects of a sodium-glucose co-transporter 2 inhibitor on the plasma amino acid profile., Jojima Teruo;Sakurai Shintaro;Kishi Haruka;Kato Kananko;Iijima Toshie;Tomaru Takuya;Usui Isao;Aso Yoshimasa, Expert opinion on pharmacotherapy, 25（7）, 937-944, 2024年06月04日

  DOI
• High serum levels of CCL11/Eotaxin-1 are associated with diabetic sensorimotor polyneuropathy and peripheral nerve function but not with cardiac autonomic neuropathy in people with type 2 diabetes., Aso Yoshimasa;Iijima Toshie;Jojima Teruo;Saito Masahiro;Tanuma Dai;Kase Masato;Sakurai Shintaro;Tomaru Takuya;Usui Isao, Postgraduate medicine, 136（3）, 318-324, 2024年04月29日

  DOI
• Patients with diabetes and obesity exhibit characteristics in eating and coping behaviors and personality traits., Saito Masahiro;Usui Isao;Sugawara Norio;Jojima Teruo;Sakurai Shintaro;Kishi Haruka;Sagara Masaaki;Tomaru Takuya;Iijima Toshie;Shimoda Kazutaka;Yasui-Furukori Norio;Aso Yoshimasa, Diabetology international, 15（3）, 528-534, 2024年04月16日

  DOI
• Impact of inpatient management of hyperglycemia on peripheral T cell markers in patients with type 2 diabetes., Kunii Tomohisa;Usui Isao;Jojima Teruo;Shimizu Masanori;Kase Masato;Sakurai Shintaro;Tomaru Takuya;Iijima Toshie;Aso Yoshimasa, Diabetology international, 15（3）, 414-420, 2024年02月26日

  DOI

総説論文
• Diabetes with GLP-1R polymorphism (rs3765467) accompanied by myotonic dystrophy: A case of myotonic dystrophy with p.R131Q polymorphism at the glucagon-like peptide-1 receptor (rs3765467) resulting in marked effects of its agonist, dulaglutide., Kato Kanako;Jojima Teruo;Kogai Takahiko;Tanuma Dai;Niitani Takafumi;Sakurai Shintaro;Iijima Toshie;Tomaru Takuya;Usui Isao;Aso Yoshimasa, The American journal of the medical sciences, 369（1）, 126-130, 2024年07月08日

  DOI

症例報告
• Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication., Shinohara Yasutake;Iijima Toshie;Sakurai Shintaro;Jojima Teruo;Ohira Eriko;Hayashi Shujiro;Usui Isao;Igawa Ken;Aso Yoshimasa, Clinical case reports, 8（10）, 2007-2012, 2020年10月

  DOIPermalink
• Genetic alteration of ARMC5 in a patient diagnosed with meningioma and primary macronodular adrenal hyperplasia: a case report., Jojima Teruo;Kogai Takahiko;Iijima Toshie;Kato Kanako;Sagara Masaaki;Kezuka Atsumi;Kase Masato;Sakurai Shintaro;Akimoto Kazumi;Sakumoto Junko;Namatame Takashi;Ueki Keisuke;Hishinuma Akira;Kamai Takao;Usui Isao;Aso Yoshimasa, European journal of endocrinology, 183（6）, K7-K12, 2020年12月

  DOIPermalink
• A case of hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome with a novel frameshift variant in GATA3, p.W10Cfs40, lacks kidney malformation., Kishi Haruka;Jojima Teruo;Kogai Takahiko;Iijima Toshie;Ohira Eriko;Tanuma Dai;Konno Sachiyo;Kato Kanako;Kezuka Atsumi;Akimoto Kazumi;Sakumoto Junko;Hishinuma Akira;Tomaru Takuya;Makita Noriko;Usui Isao;Aso Yoshimasa, Clinical case reports, 8（12）, 2619-2624, 2020年12月

  DOIPermalink
• Symptomatic hypocalcemia after treatment for hyperthyroidism in a woman with chromosome 22q11.2 deletion syndrome complicated by Graves' disease: longitudinal changes in the number of subsets of CD4 and CD8 lymphocytes after thyroidectomy., Iijima Toshie;Jojima Teruo;Hosonuma Soichiro;Ohhira Eriko;Tomaru Takuya;Kogai Takahiko;Usui Isao;Aso Yoshimasa, Endocrine journal, 68（10）, 1187-1195, 2021年10月28日

  DOIPermalink
• Thyroid storm after coronavirus disease 2019 mRNA vaccination in a patient with a history of Graves' disease after coronavirus disease 2019 infection., Saito Masahiro;Iijima Toshie;Kurai Hidetaka;Aso Yosimasa, BMJ case reports, 17（6）, 2024年06月04日

  DOI

不明
• Relationship between reduced heart rate variability and increased arterial stiffness evaluated by the cardio-ankle vascular index in people with type 2 diabetes., Kase Masato;Iijima Toshie;Niitani Takafumi;Sagara Masaaki;Sakurai Shintaro;Tomaru Takuya;Jojima Teruo;Usui Isao;Aso Yoshimasa, Diabetology international, 14（1）, 94-102, 2022年09月29日

  DOI

書籍等出版物

• 日本臨床【腎臓症候群(第2版)下-その他の腎臓疾患を含めて-】, 各種病態にみられる腎障害　内分泌疾患　自己免疫性甲状腺疾患, 共著, 日本臨床社, 2012年03月

講演・口頭発表等

• バセドウ病加療中に無顆粒球症を発症し、それを契機に発見された橋本病型IgG4関連甲状腺炎の1例, 飯嶋寿江, 2012年11月, ポスター発表, 日本甲状腺学会, 国内会議
• 甲状腺クリーゼの病態の解析・治療とその予後, 飯嶋寿江, 2012年11月, ポスター発表, 日本甲状腺学会, 国内会議
• 1型糖尿病における強化インスリン療法とGLP-1アナログliraglutideの併用療法の有効性について, 飯嶋寿江, 2012年05月, 口頭発表（一般）, 日本糖尿病学会, 国内会議
• 当院で過去5年間の2型糖尿病患者におけるミチグリニド単剤およびαGI、TZD、BG併用、BOT療法例の臨床的検討, 飯嶋寿江, 2012年05月, ポスター発表, 日本糖尿病学会, 国内会議
• GLP-1analogueの抗動脈硬化作用についての検討, 飯嶋寿江, 2012年05月, 口頭発表（一般）, 日本糖尿病学会, 国内会議
• 肥満糖尿病患者のビクトーザを用いた治療, 飯嶋寿江, 2012年05月, ポスター発表, 日本糖尿病学会, 国内会議
• 甲状腺クリーゼと糖尿病ケトアシドーシスを同時に発症した多腺性自己免疫症候群の1例, 飯嶋寿江, 2011年01月, 口頭発表（一般）, 日本糖尿病学会関東甲信越地方会, 国内会議